It was announced this past Monday that KalGene Pharmaceuticals Inc. has finished the securement of finances intended to support the development of its Alzheimer’s Therapeutic Program. Lumira Capital garnered this investment with the help of Anges Québec, Anges Québec Capital, Accel-Rx Health Sciences Accelerator and many of the Canadian family offices. With the closing of this financial series, Kalgene Pharmaceutical has seen additional financial support from other foundations leading the research industry in neurodegenerative diseases. The combined assets and funding will all go towards the advancement of their Alzheimer’s therapeutic candidate, which has made outstanding progress as a result from all of this support and work with an abundant amount of key collaboration partners. Partners which include; the National Research Council of Canada, McGill University, Weston Brain Institute, Consortium Québécois sur la découverte du médicament (CQDM), Brain Canada and Ontario Brain Institute. Dr. T. Nathan Yoganathan, President and Chief Scientific Officer of KalGene stated that they are “pleased to close on this financing which will allow us to complete our preclinical studies and move our program into the clinic and eventually have an impact on patients' lives”.
SOURCE: Newswire, November 27th, 2017
AUTHOR(S): KalGene Pharmaceuticals Inc., Newswire
DATE RETRIEVED: December 1st, 2017